Furthermore, overexpression of SETD1A in breast cancers is associated with poor clinical outcome (Fig. 1b; Logrank P = 0.0035; HR = 5.03 (1.51–16.8)), suggesting that it confers a growth advantage in multiple tumor settings. Here, SETD1A is linked to neoplasm.